Evonik targets advanced manufacturing

Global CMO Evonik has completed a €36 million expansion of advanced technologies to help boost its manufacturing capabilities across the US and Europe.

Advanced technologies, such as high-potency API, fermentation and continuous processing have been introduced by Evonik at a number of its sites over the past year.

Dr Jean-Luc Herbeaux, SVP and head of the Evonik Health Care business line said: “Evonik will continue to be a leader in advanced technologies that make the industrialisation and commercialisation of these highly specialised products possible.”

The technologies have been introduced in an effort to help Evonik customers bring specialised molecules to market using advanced manufacturing processes.

For instance, Evonik has recently commissioned a new modular cGMP continuous processing plant at its facility in Hanau, Germany, as well as a pilot plant for the custom synthesis of highly pure PEGs and mPEGS for pharmaceutical applications.

In Slovakia, Evonik has invested in a flexible pilot plant for downstream processing, making it the sixth plant in a worldwide network to support microbial fermentation projects from strain development through to commercial manufacturing.

Evonik has also increased its asset footprint and has added additional capabilities to support the production of highly potent active pharmaceutical ingredients (HPAPI). The new additions, which have been put in place at its Hanau facility, alongside a plant in Tippecanoe US, enable Evonik to run several HPAPI projects in parallel.

Dr Andreas Meudt, VP and head of exclusive synthesis at Evonik said: “Advanced technologies will continue to be deployed across our global network in response to emerging customer needs. In parallel, our commitment to quality and regulatory excellence will continue to drive all business activities.”